DVAX vs PATH · rev $277.2M vs P/E 19, rev $1.61B
Dynavax Technologies Corporation (DVAX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Dynavax Technologies Corporation (DVAX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported DVAX revenue for 2024-12-31 was $277.2M. Net income was $27.3M. Revenue was up 19.4% from 2023-12-31 to 2024-12-31. DVAX currently screens at market cap $1.82B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
DVAX currently screens at market cap $1.82B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the DVAX and PATH stock pages for the full models.
Not investment advice.